GeoVax Reaches Out to WHO, Africa CDC on Ebola Vaccine Amid Bundibugyo Outbreak
GOVX sits 19% above its 52-week low of $0.59 on elevated volume (2.1× avg).
Summary
GeoVax is expanding outreach to global health agencies about its MVA-based Ebola vaccine portfolio as the Bundibugyo virus outbreak grows. The company cites emerging evidence that the licensed Zaire Ebola vaccine may offer cross-protection against Bundibugyo, and its own candidate GEO-EM01 showed 100% protection in a non-human primate challenge. GeoVax is seeking external evaluation or partnerships without diverting resources from its lead GEO-MVA program, which remains on track for a pivotal Phase 3 start in Q4 2026. This follows the company's recent mpox/smallpox milestone and comes amid a tight cash position and Nasdaq delisting risk. The outreach could open non-dilutive development paths for a portfolio asset, but no agreements or funding are secured yet.
At the time of this announcement, GOVX was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.59 to $20.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.